Patient information
| Characteristic . | All patients (N = 49) . |
|---|---|
| Median age, y, (range) | 65 (44-79) |
| Sex | |
| Female | 11 (22.4) |
| Male | 38 (77.6) |
| Disease | |
| DLBCL | 40 (81.6) |
| tFL | 8 (16.3) |
| tCLL | 1 (2.0) |
| Stage at apheresis | |
| I/II | 8 (16.3) |
| III/IV | 41 (83.7) |
| IPI at apheresis | |
| 1-2 | 15 (30.6) |
| 3-5 | 34 (69.4) |
| ECOG at apheresis | |
| 0-1 | 38 (77.6) |
| 2-3 | 11 (22.4) |
| Median prior treatment regimens, n (range) | 2 (1-6) |
| Salvage chemotherapies | |
| Platinum compounds | 40 (81.6) |
| Cisplatin | 11 (22.4) |
| Carboplatin | 17 (34.7) |
| Oxaliplatin | 15 (30.6) |
| Melphalan | 11 (22.4) |
| Previous HDT/ASCR | 11 (22.4) |
| Bridging therapy | |
| No | 15 (30.6) |
| Yes | 34 (69.4) |
| CAR-19 product | |
| Axicabtagene ciloleucel | 45 (91.8) |
| Tisagenlecleucel | 2 (4.1) |
| Lisocabtagene maraleucel | 2 (4.1) |
| CRS grade | |
| 0 | 9 (18.4) |
| 1-2 | 36 (73.5) |
| 3-5 | 4 (8.2) |
| ICANS grade | |
| 0 | 16 (32.7) |
| 1-2 | 18 (36.7) |
| 3-4 | 15 (30.6) |
| CAR-19 treatment outcome | |
| Response without progression | 18 (36.7) |
| Response with progression (relapse) | 23 (46.9) |
| Refractory disease | 8 (16.3) |
| Characteristic . | All patients (N = 49) . |
|---|---|
| Median age, y, (range) | 65 (44-79) |
| Sex | |
| Female | 11 (22.4) |
| Male | 38 (77.6) |
| Disease | |
| DLBCL | 40 (81.6) |
| tFL | 8 (16.3) |
| tCLL | 1 (2.0) |
| Stage at apheresis | |
| I/II | 8 (16.3) |
| III/IV | 41 (83.7) |
| IPI at apheresis | |
| 1-2 | 15 (30.6) |
| 3-5 | 34 (69.4) |
| ECOG at apheresis | |
| 0-1 | 38 (77.6) |
| 2-3 | 11 (22.4) |
| Median prior treatment regimens, n (range) | 2 (1-6) |
| Salvage chemotherapies | |
| Platinum compounds | 40 (81.6) |
| Cisplatin | 11 (22.4) |
| Carboplatin | 17 (34.7) |
| Oxaliplatin | 15 (30.6) |
| Melphalan | 11 (22.4) |
| Previous HDT/ASCR | 11 (22.4) |
| Bridging therapy | |
| No | 15 (30.6) |
| Yes | 34 (69.4) |
| CAR-19 product | |
| Axicabtagene ciloleucel | 45 (91.8) |
| Tisagenlecleucel | 2 (4.1) |
| Lisocabtagene maraleucel | 2 (4.1) |
| CRS grade | |
| 0 | 9 (18.4) |
| 1-2 | 36 (73.5) |
| 3-5 | 4 (8.2) |
| ICANS grade | |
| 0 | 16 (32.7) |
| 1-2 | 18 (36.7) |
| 3-4 | 15 (30.6) |
| CAR-19 treatment outcome | |
| Response without progression | 18 (36.7) |
| Response with progression (relapse) | 23 (46.9) |
| Refractory disease | 8 (16.3) |
Data are expressed as the number of patients (percentage of the study group), unless otherwise indicated.
CRS, cytokine release syndrome; ECOG, Eastern Cooperative Oncology Group; HDT/ASCR, high-dose therapy with autologous stem-cell rescue; ICANS, immune effector cell-associated neurotoxicity syndrome; IPI, International Prognostic Index; tCLL, transformed chronic lymphocytic leukemia; tFL, transformed follicular lymphoma.